STOCK TITAN

[Form 4] Fulgent Genetics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Paul Kim, CFO and Treasurer of Fulgent Genetics, Inc. (FLGT) reported a routine disposition on 08/23/2025 in which 670 shares of common stock were disposed (transaction code F) at a price of $21.77 per share. The filing explains these shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 23, 2023. After the withholding, the reporting person beneficially owned 339,158 shares directly. The Form 4 is signed by Paul Kim on 08/26/2025.

Paul Kim, CFO e tesoriere di Fulgent Genetics, Inc. (FLGT), ha comunicato una disposizione ordinaria il 23/08/2025: sono state disposte 670 azioni di azioni ordinarie (codice transazione F) al prezzo di $21,77 per azione. La comunicazione specifica che le azioni sono state trattenute per coprire obblighi fiscali derivanti dal vesting di unità azionarie vincolate concesse il 23 febbraio 2023. Dopo la ritenuta, il dichiarante possedeva direttamente 339.158 azioni. Il Modulo 4 è firmato da Paul Kim in data 26/08/2025.

Paul Kim, CFO y tesorero de Fulgent Genetics, Inc. (FLGT), informó una disposición rutinaria el 23/08/2025 en la que se dispusieron 670 acciones ordinarias (código de transacción F) a un precio de $21,77 por acción. La presentación explica que estas acciones fueron retenidas para satisfacer obligaciones fiscales derivadas del vencimiento de unidades restringidas de acciones otorgadas el 23 de febrero de 2023. Tras la retención, la persona que informa poseía directamente 339.158 acciones. El Formulario 4 está firmado por Paul Kim el 26/08/2025.

Fulgent Genetics, Inc. (FLGT) 재무책임자 겸 재무담당관 Paul Kim은 2025년 8월 23일 일상적인 처분을 보고했으며, 해당 처분으로 보통주 670주(거래 코드 F)가 주당 $21.77에 처분되었습니다. 신고서에는 이 주식들이 2023년 2월 23일 부여된 제한 주식 단위(RSU)의 베스팅으로 인한 세금 원천징수 의무를 충족하기 위해 보류되었다고 설명되어 있습니다. 원천징수 후 신고인은 339,158주를 직접 보유하게 되었습니다. Form 4는 2025년 8월 26일 Paul Kim의 서명으로 제출되었습니다.

Paul Kim, directeur financier et trésorier de Fulgent Genetics, Inc. (FLGT), a déclaré une cession de routine le 23/08/2025 au cours de laquelle 670 actions ordinaires ont été cédées (code de transaction F) au prix de 21,77 $ par action. Le dossier précise que ces actions ont été retenues pour couvrir des obligations fiscales liées au vesting d'unités d'actions restreintes attribuées le 23 février 2023. Après la retenue, la personne déclarante détenait directement 339 158 actions. Le formulaire 4 est signé par Paul Kim le 26/08/2025.

Paul Kim, CFO und Schatzmeister von Fulgent Genetics, Inc. (FLGT), meldete am 23.08.2025 eine routinemäßige Veräußerung, bei der 670 Aktien des Stammkapitals (Transaktionscode F) zu einem Preis von $21,77 pro Aktie veräußert wurden. Die Einreichung erklärt, dass diese Aktien zur Erfüllung steuerlicher Abzugsverpflichtungen einbehalten wurden, die aus dem Vesting von Restricted Stock Units vom 23. Februar 2023 resultieren. Nach der Einbehaltung besaß die meldepflichtige Person direkt 339.158 Aktien. Das Formular 4 ist von Paul Kim am 26.08.2025 unterzeichnet.

Positive
  • Transaction is routine tax withholding tied to RSU vesting rather than an open-market sale
  • Significant remaining direct ownership: reporting person holds 339,158 shares after the withholding
Negative
  • None.

Insights

TL;DR: A small, routine tax-withholding disposition of 670 shares; reporting officer still holds substantial equity.

The reported transaction is a standard withholding to cover taxes on vested restricted stock units rather than an open-market sale aimed at liquidity. The disposed amount (670 shares at $21.77) is minor relative to the remaining direct holdings of 339,158 shares, so the event is unlikely to materially affect company ownership structure or signal a change in executive conviction. Transaction code F and the explanatory note confirm the withholding nature, which is common following RSU vesting.

TL;DR: Disclosure aligns with Section 16 requirements and includes appropriate explanatory note about tax withholding.

The Form 4 includes the required details: reporting person identity, relationship to issuer (CFO and Treasurer), transaction date, price, and post-transaction beneficial ownership. The explanatory footnote ties the disposition to RSU vesting originally reported on February 27, 2023, which aids transparency. The timely filing and manual signature dated 08/26/2025 meet procedural expectations for insider reporting.

Paul Kim, CFO e tesoriere di Fulgent Genetics, Inc. (FLGT), ha comunicato una disposizione ordinaria il 23/08/2025: sono state disposte 670 azioni di azioni ordinarie (codice transazione F) al prezzo di $21,77 per azione. La comunicazione specifica che le azioni sono state trattenute per coprire obblighi fiscali derivanti dal vesting di unità azionarie vincolate concesse il 23 febbraio 2023. Dopo la ritenuta, il dichiarante possedeva direttamente 339.158 azioni. Il Modulo 4 è firmato da Paul Kim in data 26/08/2025.

Paul Kim, CFO y tesorero de Fulgent Genetics, Inc. (FLGT), informó una disposición rutinaria el 23/08/2025 en la que se dispusieron 670 acciones ordinarias (código de transacción F) a un precio de $21,77 por acción. La presentación explica que estas acciones fueron retenidas para satisfacer obligaciones fiscales derivadas del vencimiento de unidades restringidas de acciones otorgadas el 23 de febrero de 2023. Tras la retención, la persona que informa poseía directamente 339.158 acciones. El Formulario 4 está firmado por Paul Kim el 26/08/2025.

Fulgent Genetics, Inc. (FLGT) 재무책임자 겸 재무담당관 Paul Kim은 2025년 8월 23일 일상적인 처분을 보고했으며, 해당 처분으로 보통주 670주(거래 코드 F)가 주당 $21.77에 처분되었습니다. 신고서에는 이 주식들이 2023년 2월 23일 부여된 제한 주식 단위(RSU)의 베스팅으로 인한 세금 원천징수 의무를 충족하기 위해 보류되었다고 설명되어 있습니다. 원천징수 후 신고인은 339,158주를 직접 보유하게 되었습니다. Form 4는 2025년 8월 26일 Paul Kim의 서명으로 제출되었습니다.

Paul Kim, directeur financier et trésorier de Fulgent Genetics, Inc. (FLGT), a déclaré une cession de routine le 23/08/2025 au cours de laquelle 670 actions ordinaires ont été cédées (code de transaction F) au prix de 21,77 $ par action. Le dossier précise que ces actions ont été retenues pour couvrir des obligations fiscales liées au vesting d'unités d'actions restreintes attribuées le 23 février 2023. Après la retenue, la personne déclarante détenait directement 339 158 actions. Le formulaire 4 est signé par Paul Kim le 26/08/2025.

Paul Kim, CFO und Schatzmeister von Fulgent Genetics, Inc. (FLGT), meldete am 23.08.2025 eine routinemäßige Veräußerung, bei der 670 Aktien des Stammkapitals (Transaktionscode F) zu einem Preis von $21,77 pro Aktie veräußert wurden. Die Einreichung erklärt, dass diese Aktien zur Erfüllung steuerlicher Abzugsverpflichtungen einbehalten wurden, die aus dem Vesting von Restricted Stock Units vom 23. Februar 2023 resultieren. Nach der Einbehaltung besaß die meldepflichtige Person direkt 339.158 Aktien. Das Formular 4 ist von Paul Kim am 26.08.2025 unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kim Paul

(Last) (First) (Middle)
C/O FULGENT GENETICS, INC.
4399 SANTA ANITA AVENUE

(Street)
EL MONTE CA 91731

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO and Treasurer
3. Date of Earliest Transaction (Month/Day/Year)
08/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/23/2025 F 670(1) D $21.77 339,158 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023.
/s/ Paul Kim 08/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did FLGT insider Paul Kim report on Form 4?

The filing reports a disposition of 670 common shares on 08/23/2025 at $21.77 per share (transaction code F).

Why were the 670 shares disposed according to the Form 4?

The shares were withheld to satisfy tax withholding obligations from the vesting of restricted stock units granted on February 23, 2023.

How many FLGT shares does Paul Kim beneficially own after the transaction?

After the reported withholding, Paul Kim beneficially owns 339,158 shares directly.

What is Paul Kim's role at Fulgent Genetics as listed on the Form 4?

The Form 4 lists Paul Kim as a Director and as an Officer (CFO and Treasurer) of Fulgent Genetics, Inc.

When was the Form 4 signed by the reporting person?

The Form 4 is signed by Paul Kim on 08/26/2025.
Fulgent Genetics

NASDAQ:FLGT

FLGT Rankings

FLGT Latest News

FLGT Latest SEC Filings

FLGT Stock Data

662.38M
20.45M
33.21%
53.88%
6.83%
Diagnostics & Research
Services-medical Laboratories
Link
United States
EL MONTE